2. Search Result
Search Result
Results for "

phosphotyrosine

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

3

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

1

Natural
Products

3

Recombinant Proteins

9

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116022A
    4-Nitrophenyl phosphate disodium hexahydrate
    2 Publications Verification

    p-Nitrophenyl phosphate disodium hexahydrate

    		 Biochemical Assay Reagents Others
    4-Nitrophenyl phosphate (p-nitrophenyl phosphate) disodium hexahydrate is widely used as a small molecule phosphotyrosine-like substrate in activity assays for protein tyrosine phosphatases. 4-Nitrophenyl phosphate disodium hexahydrate is a colorless substrate that upon hydrolysis is converted to a yellow 4-nitrophenolate ion that can be monitored by absorbance at 405 nm .
    4-Nitrophenyl phosphate disodium hexahydrate
  • HY-116022
    4-Nitrophenyl phosphate
    3 Publications Verification

    p-Nitrophenyl phosphate

    		 Biochemical Assay Reagents Others
    4-Nitrophenyl phosphate (p-Nitrophenyl phosphate) is widely used as a small molecule phosphotyrosine-like substrate in activity assays for protein tyrosine phosphatases.4-Nitrophenyl phosphate is a colorless substrate that upon hydrolysis is converted to a yellow 4-nitrophenolate ion that can be monitored by absorbance at 405 nm .
    4-Nitrophenyl phosphate
  • HY-W089800
    trans-2-Nonenal

    trans-2-Nonen-1-al

    		 COX Lipoxygenase Apoptosis Cardiovascular Disease Inflammation/Immunology
    trans-2-Nonenal (trans-2-Nonen-1-al) is an endogenous peroxidation product of polyunsaturated fatty acids, acting as an inhibitor of COX and 12-LOX, as well as an inducer of apoptosis. trans-2-Nonenal is also a malodorous compound secreted by the human body, and its content gradually increases with aging. trans-2-Nonenal inhibits the activities of multiple enzymes such as platelet membrane-bound PTPase, preferentially covalently modifies proteins at lysine residues to form immunogenic adducts, and regulates platelet Arachidonic acid (HY-109590) metabolism. trans-2-Nonenal also exhibits significant cytotoxicity, reduces the viability of keratinocytes, promotes their apoptosis, and effectively decreases the thickness of epidermal models and the number of proliferating cells. trans-2-Nonenal is commonly used in studies of thrombotic, atherosclerotic diseases, renal adenocarcinoma, etc. .
    trans-2-Nonenal
  • HY-155978A
    RDN2150 TFA
    1 Publications Verification

    		 Tyrosinase ERK Interleukin Related IFNAR Inflammation/Immunology
    RDN2150 TFA is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 TFA inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 TFA can be used for psoriasis-related research .
    RDN2150 TFA
  • HY-P10665
    pYEEI

    		Src Cancer
    pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
    pYEEI
  • HY-129510
    4-Methyl erlotinib

    		EGFR Mitosis Cancer
    4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .
    4-Methyl erlotinib
  • HY-155978
    RDN2150

    		Tyrosinase IFNAR ERK Interleukin Related Inflammation/Immunology
    RDN2150 is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 can be used for psoriasis-related research .
    RDN2150
  • HY-16906
    T338C Src-IN-2

    		Src Cancer
    T338C Src-IN-2 is a mutant c-Src kinase inhibitor, with an IC50 of 317 nM against T338C c-Src, 57 nM against T338C/V323A c-Src, and 19 nM against T338C/V323S c-Src. T338C Src-IN-2 inhibits the kinase activity of endogenous cysteine gatekeeper MOK. T338C Src-IN-2 reduces global phosphotyrosine levels in v-Src-ES1-transformed NIH-3T3 cells .
    T338C Src-IN-2
  • HY-161549
    Phosphotyrosine/BSA

    		Biochemical Assay Reagents Inflammation/Immunology
    Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Phosphotyrosine/BSA
  • HY-12135
    Poloxipan

    		Polo-like Kinase (PLK) PIN1 STAT Cancer
    Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
    Poloxipan
  • HY-129510R
    4-Methyl erlotinib (Standard)

    		EGFR Mitosis Reference Standards Cancer
    4-Methyl erlotinib (Standard) is the analytical standard of 4-Methyl erlotinib. This product is intended for research and analytical applications. 4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .
    4-Methyl erlotinib (Standard)
  • HY-206735
    CDC14A/B-IN-2

    		Phosphatase Cancer
    CDC14A/B-IN-2, phosphotyrosine mimetic, is a competitive human CDC14A/B phosphatase inhibitor with IC50 values of 10.4 and 11.2 μM, and Ki values of 5.8 and 7.3 μM. CDC14A/B-IN-2 shows at least 20-fold selectivity over other protein tyrosine phosphatases. CDC14A/B-IN-2 can be used for the research of cancer .
    CDC14A/B-IN-2
  • HY-183840
    PP185

    		Insulin Receptor Neurological Disease Cancer
    PP185 is a insulin receptor kinase substrate. PP185 undergoes rapid tyrosine phosphorylation, with activity dependent on divalent cations and inhibited by insulin receptor kinase domain antibodies. PP185 can be used for the research of neuroblastoma .
    PP185

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: